Current:Home > MySafeX Pro Exchange|Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers. -AssetTrainer
SafeX Pro Exchange|Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Will Sage Astor View
Date:2025-04-10 00:40:09
Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and SafeX Pro Exchangediabetes drug Ozempic than it does patients in Europe.
Novo Nordisk CEO Lars Fruergaard Jørgensen appeared before the Senate Committee on Health, Education, Labor and Pensions. The committee is chaired by Sen. Bernie Sanders, a Vermont independent who launched an investigation this year into Novo Nordisk's drug pricing.
Novo Nordisk has made nearly $50 billion on the sales of Ozempic and Wegovy since 2018, Sanders said. He described the U.S. as a "cash cow" for Novo Nordisk, accounting for 72% of the company's worldwide sales of those two drugs.
Among questions posed by Sanders: Why do Americans pay far more for these medications than patients in other countries?
Sanders opened the hearing by displaying charts comparing Novo Nordisk's prices charged to Americans and Europeans. The company charges U.S. residents $969 a month for Ozempic, but the same drug costs $155 in Canada, $122 in Denmark, and $59 in Germany.
For the weight-loss drug Wegovy, Americans pay $1,349 a month. The drug can be purchased for $186 in Denmark, $140 in Germany, and $92 in the United Kingdom, according to Sanders' charts.
"Nobody here is asking Novo Nordisk to provide charity to the American people," Sanders said. "All we are saying, Mr. Jørgensen, is treat the American people the same way that you treat people all over the world. Stop ripping us off."
Jørgensen defended the company's pricing of the wildly popular medications and said 80% of Americans can get these drugs for $25 or less per month.
He said U.S. list prices can't be compared to prices charged in other countries, in part, due to the nation's complex structure. U.S. prices are influenced by health insurance companies and drug-pricing middlemen called pharmacy benefit managers.
Jørgensen said the diabetes drug Ozempic is covered by the vast majority of private health insurance plans, as well as Medicare and Medicaid, the government health insurance programs for seniors and low-income families. Wegovy is covered by about half of private health insurers, Medicaid plans in 20 states and the Department of Veterans Affairs.
"You have said that our amazing medicines can't help patients if they can't afford them ‒ that is true," Jørgensen said. "It is also true that the full value of Ozempic and Wegovy can only be realized if patients can access them. Patients need affordability and access."
Medicare, the federal health program for adults 65 and older, is prohibited by law from covering drugs for those who are obese but otherwise do not have serious risk factors. But obese patients with diabetes or heart disease may qualify for coverage. The nonprofit health policy organization KFF estimated that 1 in 4 Medicare enrollees who are obese may be eligible for Wegovy to reduce their risk of heart attack or stroke.
The committee also highlighted a March study from researchers at Yale University found these drugs could be made for less than $5 a month, or $57 per year. Last week, Sanders announced CEOs of major generic pharmaceutical companies would be willing to sell Ozempic to Americans for less than $100 per month, at a profit. However, such estimates do not account for the expensive costs of researching and developing drugs and testing them in clinical trials.
Jørgensen said Novo Nordisk scientists have worked on the weight-loss drugs since the early 1990s. The company also has committed $30 billion to expand manufacturing capacity to address supply shortages of the medications.
Representatives of drug industry's trade group PhRMA said health insurers and pharmacy benefit managers deserve more scrutiny when it comes to drug affordability.
“The one question everyone should be asking is why aren’t insurers and PBMs being forced to answer for denying coverage and driving up patients’ costs?" said Alex Schriver, senior vice president of public affairs at PhRMA: "Senator Sanders continues repeating the same misleading rhetoric on drug prices. But why won’t he talk about how insurance conglomerates are taking in record profits or how PBMs are being investigated and sued for their abusive tactics?"
veryGood! (96645)
Related
- Tree trimmer dead after getting caught in wood chipper at Florida town hall
- 'Kia Boys' flee police in Washington before crashing, chopper footage shows
- A new election law battle is brewing in Georgia, this time over voter challenges
- Trump barred from attacks on judge's daughter in New York hush money case gag order
- At site of suspected mass killings, Syrians recall horrors, hope for answers
- The amount of money Americans think they need to retire comfortably hits record high: study
- Germany changes soccer team jerseys over Nazi symbolism concerns
- Workers had little warning as Maryland bridge collapsed, raising concerns over safety, communication
- Moving abroad can be expensive: These 5 countries will 'pay' you to move there
- Medicaid expansion plans and school funding changes still alive in Mississippi Legislature
Ranking
- California DMV apologizes for license plate that some say mocks Oct. 7 attack on Israel
- 'Kia Boys' flee police in Washington before crashing, chopper footage shows
- Major interstate highway shut down in Philadelphia after truck hits bridge
- Police continue search for Nashville shooting suspect who has extensive criminal history
- Global Warming Set the Stage for Los Angeles Fires
- Watch these professional soccer players' kind gesture for young fans in the pouring rain
- Who is Don Hankey, the billionaire whose insurance firm provided Trump a $175 million bond payment?
- Florida man sentenced to prison for threatening to kill Supreme Court Chief Justice John Roberts
Recommendation
Could Bill Belichick, Robert Kraft reunite? Maybe in Pro Football Hall of Fame's 2026 class
Cal-Maine Foods, largest producer of eggs in US, finds bird flu in chickens at Texas plant
Diddy's ex Misa Hylton threatens legal action over 'excessive' force against son in raid
Brilliant performance from Paige Bueckers sets up showdown with Caitlin Clark, again
Retirement planning: 3 crucial moves everyone should make before 2025
Drawing nears for $1.09 billion Powerball jackpot that is 9th largest in US history
Stock market today: Asian shares drop after Wall Street sinks on rate worries
Diddy's ex Misa Hylton threatens legal action over 'excessive' force against son in raid